Added to YB: 2026-09-21
Pitch date: 2026-09-17
ALLO [neutral]
Allogene Therapeutics, Inc.
-2.31%
current return
Author Info
No bio for this author
Company Info
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Market Cap
$583.9M
Pitch Price
$1.73
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.11
P/E
-2.60
EV/Sales
71.18
Sector
Biotechnology
Category
growth
Biotech Conferences Week 2 Day 3 Part 2 - Allogene Therapeutics, Inc.
ALLO (quick overview): With a 76 M&A Score and 72 Growth Score, Allogene is a credible strategic target or partner candidate. The near-term case turns on Q4 2026 ALLO-329 autoimmune data; a convincing no-lymphodepletion profile could expand the addressable population. Longer-term value depends on cema-cel turning early MRD clearance—7 of 12 treated versus 2 of 12 observed—into EFS benefit in ALPHA3’s 2028 primary analysis. About $420 million supports runway into 2029, while efficacy, safety, durability, competition, and MRD-testing adoption remain key risks.
Read full article (2 min)